-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] Next week (February 14-February 20), 3 new A shares will be subscribed for, including Hongying Intelligent, Han's CNC, and West Point Pharmaceuticals
.
Among them, West Point Pharmaceutical Co.
, Ltd.
is a new pharmaceutical stock.
The company is a technology-based pharmaceutical enterprise focusing on the research and development, production and sales of chemical raw materials and preparations.
Drugs for mental disorders and APIs are the core, and the product system is supplemented by drugs for cardiovascular and cerebrovascular diseases and anti-tumor drugs
.
The prospectus shows that West Point Pharmaceuticals plans to issue 20,200,986 shares for the first time, accounting for 25.
00% of the total share capital after the issuance
.
After the public offering, the total share capital is 80.
803943 million shares
.
The subscription date is February 14, 2022
.
Financial data shows that from 2018 to 2020, the company achieved net profits attributable to owners of the parent company of 41.
3602 million yuan, 54.
6135 million yuan and 49.
7424 million yuan respectively, with a three-year compound annual growth rate of net profit attributable to the parent company of 10.
43%; In the same period, the operating income was 280 million yuan/325 million yuan/286 million yuan respectively, and the annual compound growth rate of the three-year operating income was 1.
07%
.
According to the company's third quarterly report in 2021, the company's operating income was 207 million yuan, a year-on-year growth rate of 1.
54%; the company's net profit attributable to the parent was 34 million yuan, a year-on-year growth rate of 2.
86%
.
The company expects the growth rate of net profit attributable to the parent company in 2021 to be -9.
53% to 2.
53%
.
The company plans to raise funds of about 341 million yuan, which will be used for the construction of comprehensive solid preparation workshops, the construction of modern extraction workshops for traditional Chinese medicine, the production of escitalopram oxalate raw materials, the construction of R&D centers, and the construction of marketing networks.
.
Chemical raw materials are located in the upstream of the pharmaceutical industry chain, and are the basis for ensuring the production of downstream preparations and meeting the needs of clinical drugs
.
China is a big country in the production and export of APIs.
Data show that in 2020, the total output of APIs included in the statistics in China will exceed 2 million tons, and the operating income will be nearly 400 billion yuan, accounting for 16% of the total pharmaceutical manufacturing industry
.
In recent years, with the tightening of environmental protection requirements, the transformation and upgrading of the API industry has been accelerated, and the industry threshold has been raised, which will become a new competitive advantage for enterprises that strictly follow green standards and have lower carbon emissions
.
Some analysts pointed out that West Point Pharmaceutical has a mature production system of raw materials, and it produces ferrous sulfate, the main raw material required by Yiyuansheng.
At the same time, the company has domestic production advantages of daphnetin raw materials, which can ensure the supply of daphnetin capsule raw materials.
Effectively reduce the company's raw material drug supply risk
.
The company's API industry layout ensures the high standard and consistency of preparation quality from the source, and ensures the stability of API supply
.
At the same time, the preparation of APIs is also the basis of drug research and development, and is the initial stage of drug research.
The company's production and processing capabilities of APIs provide an effective guarantee for formulation R&D innovation
.
Huajin Securities also stated in a recent report that West Point Pharmaceuticals has the advantage of integrating APIs
.
The company has a mature production system of raw materials, which can produce and meet the main raw material ferrous sulfate required by Yiyuansheng.
At the same time, the company has the domestic production advantages of daphnetin raw materials, which can ensure the supply of daphnetin capsule raw materials
.
In addition, the company's products have differentiated competitive advantages in dosage forms, specifications, and production processes
.
.
Among them, West Point Pharmaceutical Co.
, Ltd.
is a new pharmaceutical stock.
The company is a technology-based pharmaceutical enterprise focusing on the research and development, production and sales of chemical raw materials and preparations.
Drugs for mental disorders and APIs are the core, and the product system is supplemented by drugs for cardiovascular and cerebrovascular diseases and anti-tumor drugs
.
The prospectus shows that West Point Pharmaceuticals plans to issue 20,200,986 shares for the first time, accounting for 25.
00% of the total share capital after the issuance
.
After the public offering, the total share capital is 80.
803943 million shares
.
The subscription date is February 14, 2022
.
Financial data shows that from 2018 to 2020, the company achieved net profits attributable to owners of the parent company of 41.
3602 million yuan, 54.
6135 million yuan and 49.
7424 million yuan respectively, with a three-year compound annual growth rate of net profit attributable to the parent company of 10.
43%; In the same period, the operating income was 280 million yuan/325 million yuan/286 million yuan respectively, and the annual compound growth rate of the three-year operating income was 1.
07%
.
According to the company's third quarterly report in 2021, the company's operating income was 207 million yuan, a year-on-year growth rate of 1.
54%; the company's net profit attributable to the parent was 34 million yuan, a year-on-year growth rate of 2.
86%
.
The company expects the growth rate of net profit attributable to the parent company in 2021 to be -9.
53% to 2.
53%
.
The company plans to raise funds of about 341 million yuan, which will be used for the construction of comprehensive solid preparation workshops, the construction of modern extraction workshops for traditional Chinese medicine, the production of escitalopram oxalate raw materials, the construction of R&D centers, and the construction of marketing networks.
.
Chemical raw materials are located in the upstream of the pharmaceutical industry chain, and are the basis for ensuring the production of downstream preparations and meeting the needs of clinical drugs
.
China is a big country in the production and export of APIs.
Data show that in 2020, the total output of APIs included in the statistics in China will exceed 2 million tons, and the operating income will be nearly 400 billion yuan, accounting for 16% of the total pharmaceutical manufacturing industry
.
In recent years, with the tightening of environmental protection requirements, the transformation and upgrading of the API industry has been accelerated, and the industry threshold has been raised, which will become a new competitive advantage for enterprises that strictly follow green standards and have lower carbon emissions
.
Some analysts pointed out that West Point Pharmaceutical has a mature production system of raw materials, and it produces ferrous sulfate, the main raw material required by Yiyuansheng.
At the same time, the company has domestic production advantages of daphnetin raw materials, which can ensure the supply of daphnetin capsule raw materials.
Effectively reduce the company's raw material drug supply risk
.
The company's API industry layout ensures the high standard and consistency of preparation quality from the source, and ensures the stability of API supply
.
At the same time, the preparation of APIs is also the basis of drug research and development, and is the initial stage of drug research.
The company's production and processing capabilities of APIs provide an effective guarantee for formulation R&D innovation
.
Huajin Securities also stated in a recent report that West Point Pharmaceuticals has the advantage of integrating APIs
.
The company has a mature production system of raw materials, which can produce and meet the main raw material ferrous sulfate required by Yiyuansheng.
At the same time, the company has the domestic production advantages of daphnetin raw materials, which can ensure the supply of daphnetin capsule raw materials
.
In addition, the company's products have differentiated competitive advantages in dosage forms, specifications, and production processes
.
